Evaluation of cellular responses for a chimeric HBsAg-HCV core DNA vaccine in BALB/c mice

Yazdanian, Maryam; Memarnejadian, Arash; Mahdavi, Mohammad; Motevalli, Fatemeh; Sadat, Seyed Mehdi; Vahabpour, Rouhollah; Khanahmad, Hossein; Soleimanjahi, Hoorieh; Budkowska, Agata; Roohvand, Farzin

doi:10.4103/2277-9175.148296

Cited by 8 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CTLs were assessed in vivo as previously described ( 24 ). In brief, splenocytes from naive BALB/c mice (H-2d) were equally divided into two parts and incubated with carboxyfluorescein (CFSE) at either a low (0.5 µM) or a high concentration (5 µM).…”

Section: Methodsmentioning

confidence: 99%

Improvement of cytomegalovirus pp65 DNA vaccine efficacy by co-administration of siRNAs targeting BAK and BAX

Liu¹,

Feng

Zhao³

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

The efficacy of DNA vaccines may be improved by small interfering (si)RNA adjuvants targeting pro-apoptotic genes. The aim of the present study was to investigate the capacity of siRNAs targeting B-cell lymphoma 2 homologous antagonist killer (BAK) and B-cell lymphoma 2-associated X protein (BAX) to improve the efficacy of a cytomegalovirus (CMV) vaccine. BALB/c mice were divided into four groups (n=18 in each): unimmunized and immunized with pcDNA 3.1-pp65 expressing CMV 65 kDa matrix phosphoprotein and BAK + BAX siRNAs, pcDNA 3.1-pp65 and control siRNA, or control pcDNA 3.1 and BAK + BAX siRNAs. Immunizations were performed twice with an interval of 3 weeks. CMV-specific mouse splenocyte interferon (IFN)-γ secretion was assessed by ELISPOT; furthermore, an in vivo cytotoxic T lymphocyte assay was performed 2 weeks after the last immunization. After lethal CMV challenge of the mice, body weight, virus titers in the spleens and salivary glands as well as survival were recorded. The amount of splenocytes secreting IFN-γ in response to CMV pp65 peptides and specific lysis of peptide-pulsed target cells were significantly higher in mice administered pcDNA3.1-pp65 and BAK + BAX siRNAs than those in mice administered pcDNA3.1-pp65 and control siRNA (P<0.05 for each). After the virus challenge, the virus titers in the spleens and salivary glands of mice given pcDNA3.1-pp65 and BAK + BAX siRNAs were significantly lower than those in mice immunized with pcDNA3.1-pp65 and control siRNA (P<0.05 for each). Furthermore, mice immunized with pcDNA 3.1-pp65 and control siRNA or BAK + BAX siRNAs survived for longer, and at 21 days after lethal CMV challenge, 66 and 100% of these mice survived, respectively. These mice also experienced less weight loss compared with mice immunized with pcDNA3.1-pp65 and control siRNA (P<0.05). In conclusion, intradermal administration of siRNAs targeting BAK and BAX improved the efficacy of CMV pp65 DNA vaccine.

show abstract

Section: Methodsmentioning

confidence: 99%

Improvement of cytomegalovirus pp65 DNA vaccine efficacy by co-administration of siRNAs targeting BAK and BAX

Liu¹,

Feng

Zhao³

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…Levels of IL-4 and interferon-γ in serum were detected with test kits, in accordance with the manufacturer's instructions (YuanYe, China) [22,23] . Standard curve using a dilution series of IL-4 (256 pg/mL, 128 pg/mL, 64 pg/mL, 32 pg/mL, 16 pg/mL, 0 pg/mL) and IFN-γ (400 pg/mL, 200 pg/mL, 100 pg/mL, 50 pg/mL, 25 pg/mL, 0 pg/mL) were prepared.…”

Section: Detection Of Cytokinesmentioning

confidence: 99%

Adjuvant Domuz IL-12 ile Kombine Transmissible Gastroenteritis Virüs Spike Geni Taşıyan DNA Aşı Domuzlarda Bağışıklık Yanıtı İyileştirir

Li¹,

Li²,

Chen³

et al. 2018

Kafkas Univ Vet Fak Derg

View full text Add to dashboard Cite

Transmissible gastroenteritis (TGE), cause by transmissible gastroenteritis virus (TGEV), is an acute digestive and highly infectious disease in piglets. In this study, porcine interleukin-12 immunological adjuvant combined with a DNA vaccine bearing the TGEV-S1 gene was used to immunize piglets, and assessed the immune response of piglets. The results showed that CD4 + and CD8 + CD28 + T lymphocytes were significantly increased in immunized piglets compared to control groups. In addition, the observed increase of IFN-γ suggested that T helper cells tended to convert to Th1 cells during immune response. HE stain and indirect immunofluorescence assays indicated obvious differences between the immunized piglets and the controls, suggesting that immunized piglets suffered less pathological changes relative to piglets in the control groups. Moreover, the levels of anti-TGEV and neutralizing antibodies in serum also indicated an effective immune response in the immunized piglets by which the pathogen was rapidly controlled. Altogether, our results suggest that the combination of pVAX1-(pIL-12) and pVAX1-(TGEV-S1) in a vaccine is capable of producing a significantly enhanced immune response in piglets.

show abstract

“…Hepatitis C virus (HCV) particle contains a single‑stranded positive‑sense RNA genome that encodes a single polyprotein which is further processed to generate at least 11 polypeptides/proteins, including three structural proteins (core, and envelope proteins E1 and E2), a small polypeptide named p7, the novel F protein, and six nonstructural (NS) proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) [ 1 , 2 ]. At present, infection with HCV poses a significant threat to global health and is associated with significant mortality and morbidity worldwide.…”

Section: Introductionmentioning

confidence: 99%

Hepatitis C virus DNA vaccines: a systematic review

Shayeghpour

Kianfar

Hosseini

et al. 2021

Virol J

View full text Add to dashboard Cite

Background Vaccination against HCV is an effective measure in reduction of virus-related public health burden and mortality. However, no prophylactic vaccine is available as of yet. DNA-based immunization is a promising modality to generate cellular and humoral immune responses. The objective of this study is to provide a systematic review of HCV DNA vaccines and investigate and discuss the strategies employed to optimize their efficacies. Methods MEDLINE (PubMed), Web of Science, Scopus, ScienceDirect, and databases in persian language including the Regional Information Centre for Science & Technology (RICeST), the Scientific Information Database and the Iranian Research Institute for Information Science and Technology (IranDoc) were examined to identify studies pertaining to HCV nucleic acid vaccine development from 2000 to 2020. Results Twenty-seven articles were included. Studies related to HCV RNA vaccines were yet to be published. A variety of strategies were identified with the potential to optimize HCV DNA vaccines such as incorporating multiple viral proteins and molecular tags such as HBsAg and Immunoglobulin Fc, multi-epitope expression, co-expression plasmid utilization, recombinant subunit immunogens, heterologous prime-boosting, incorporating NS3 mutants in DNA vaccines, utilization of adjuvants, employment of less explored methods such as Gene Electro Transfer, construction of multi- CTL epitopes, utilizing co/post translational modifications and polycistronic genes, among others. The effectiveness of the aforementioned strategies in boosting immune response and improving vaccine potency was assessed. Conclusions The recent progress on HCV vaccine development was examined in this systematic review to identify candidates with most promising prophylactic and therapeutic potential.

show abstract

Evaluation of cellular responses for a chimeric HBsAg-HCV core DNA vaccine in BALB/c mice

Cited by 8 publications

References 26 publications

Improvement of cytomegalovirus pp65 DNA vaccine efficacy by co-administration of siRNAs targeting BAK and BAX

Improvement of cytomegalovirus pp65 DNA vaccine efficacy by co-administration of siRNAs targeting BAK and BAX

Adjuvant Domuz IL-12 ile Kombine Transmissible Gastroenteritis Virüs Spike Geni Taşıyan DNA Aşı Domuzlarda Bağışıklık Yanıtı İyileştirir

Hepatitis C virus DNA vaccines: a systematic review

Contact Info

Product

Resources

About